Eli Lilly & Co. (LLY) Raises Quarterly Dividend 14.7% to $0.645; 2.4% Yield

After-Hours Movers 12/18: (ADRO) (JBL) Higher; (SURF) (MU) (FDX) (more...)

After-Hours Movers

Aduro Biotech, Inc. (NASDAQ: ADRO) 26.3% HIGHER; Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases.

Surface Oncology (Nasdaq: SURF) 16.6% LOWER; announced today updates related to its product pipeline, notably the... More

Eli Lilly & Co. (LLY), Aduro Biotech, Inc. (ADRO) Report Research Collaboration & License Agreement to Develop Novel Immunotherapies

Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases.

Aduro's cGAS-STING Pathway Inhibitor program aims to discover and develop inhibitors of the intracellular stimulator of interferon genes (STING) pathway, which can modulate the immune response associated with various autoimmune diseases. As part of the... More

Lilly (LLY) announces publication of analyses showing benefit of addition of Verzenio in multiple subgroups of patients with advanced breast cancer

Eli Lilly and Company (NYSE: LLY) today announced npj Breast Cancer published results from exploratory subgroup analyses of the MONARCH 2 and MONARCH 3 trials reinforcing the clinical benefit of Verzenio® (abemaciclib) plus endocrine therapy in the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The analyses demonstrate that while the benefit of the addition of Verzenio was seen across all patient subgroups, consistent with the individual study... More

Lilly (LLY) Says Taltz met primary and all major secondary endpoints in Phase 3b/4 SPIRIT-H2H study

Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira® (adalimumab) in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naive. The SPIRIT-H2H trial is the first completed large head-to-head (H2H) superiority study in active PsA. This open-label, randomized, controlled trial is the first and only H2H study that utilizes on-label dosing for both Taltz and Humira and includes concomitant conventional... More